Our study cohort was selected to be similar to that of a clinical trial of testosterone treatment: no testosterone treatment in the prior year; no previous diagnosis of prostate or breast cancer; and a serum PSA level < 4 ng/dL. Here, KLK3 is linked to breast cancer.